Key result
RDN significantly lowers BP compared to sham control in patients with hypertension.
Why the study?
Hypertension significantly increases cardiovascular risk and current treatments rely mainly on medication and lifestyle changes, prompting investigation into renal denervation as a novel therapy.
Renal denervation may serve as adjunctive therapy in hypertension; leaves open questions on long-term outcomes and optimal patient selection.
Hypertension can lead to a significant increase in the risk of cardiovascular events, with a high rate of disability and mortality. It is one of the common causes of cardiovascular and cerebrovascular accidents, which seriously affect patients’ quality of life and lifespan. Currently, treatment strategies for hypertension are mainly based on medication and lifestyle interventions. The renal sympathetic nervous system plays an important role in the pathogenesis of hypertension, and catheter-based renal denervation (RDN) provides a new concept for the treatment of hypertension. In recent years, studies on RDN have been carried out worldwide. This article reviews the latest preclinical research and clinical evidence.
No takes yet. Share an insight, caveat, or question.
Xiong et al. (2023) conducted a review in Hypertension. Renal denervation vs. Sham procedure or standard antihypertensive therapy was evaluated. Renal denervation provides a promising interventional approach for lowering blood pressure in patients with hypertension, with recent trials demonstrating significant blood pressure reductions compared to sham procedures.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: